Post-authorisation | State Agency of Medicines of the Republic of Latvia

Renewal of marketing authorisation

The decision regarding marketing authorisation of a new medicinal product stays in effect for five years after its adoption. After five years have elapsed since adoption of decision regarding marketing authorisation, a decision is adopted regarding renewal of authorisation, based on evaluation of the risk and benefit ratio. The State Agency of Medicines (SAM) may adopt a decision regarding renewal of authorisation for an unlimited period of time. If based on evidence from monitoring of adverse drug reactions, SAM is of the opinion that another renewal is required, it may adopt a decision to renew authorisation for another five years. In order to reach a common renewal date among the member states involved in a mutual recognition procedure, the marketing authorisation of the relevant medicinal product may be renewed before five years have elapsed.

The renewal procedure is conducted in accordance with the European Union (EU) legal acts and approved guidance, as well as the Cabinet of Ministers regulations regarding the procedure for marketing authorisation of medicinal products.

The application for renewal of marketing authorisation must be submitted to SAM at least 9 months prior to the expiration date of the marketing authorisation of a medicinal product.

The application for renewal of marketing authorisation granted via the national procedure must be submitted to SAM. If the medicinal product is authorised through the mutual recognition procedure or decentralised procedure, the application for renewal must be submitted simultaneously to the reference member state and all of the concerned member states.

Submission of documents for renewal of marketing authorisation

The application form and supporting documentation for renewal of marketing authorisation of medicinal products must be submitted electronically using Common European Submission Portal (CESP) complying with the European guidelines for preparation and submission of documentation in the eCTD (electronic Common Technical Document) format.
The application form is available on eSubmission: EU Electronic Application Forms.
Upon submission of documents for renewal of marketing authorisation, an advance payment must be made and the following documents must be attached to the marketing authorisation application:
- Copy of the invoice issued by SAM;
- A payment confirmation or print-out of the payment made via internet bank transfer verified by the credit institution confirming the advance payment;
- SAM cash register check, if payment was made with a payment card.

See more in the section “Payment procedure”.

Parallel to submission of application for renewal of marketing authorisation via the national procedure, product information (summary of product characteristics, package leaflet and labelling text) in Latvian and in Word format must be sent to the following SAM e‑mail address NP_PI@zva.gov.lv.

Payment procedure

For this service advance payment should be made in accordance with the Paid Service Pricelist (Article 2, 3, 4):

Additional fee for each additional medicinal product strength and/or pharmaceutical form, if submitted together with the initial marketing authorisation application1 (except Sections 1.10. and 1.11.), Paragraph 2:

- Renewal of marketing authorisation (including duplicate), Paragraph 2.1. - 700.00 EUR

Expertise on application and additional documentation for renewal of marketing authorisation - first strength (Paragraph 3):

- For medicinal products authorised via national, mutual recognition, decentralised authorisation procedure (1 expertise on documentation), Paragraph 3.1. - 2000.00 EUR

- For homeopathic and anthroposophic medicinal products, 1 pharmaceutical form or 1 strength (1 expertise on documentation), Paragraph 3.2. - 300.00 EUR

- For traditional-use herbal medicinal products, 1 pharmaceutical form or 1 strength (1 expertise on documentation), Paragraph 3.3. - 300.00 EUR

Additional fee for performing tasks for Latvia as a reference member state in a mutual recognition or decentralised procedure (Paragraph 4):

- For renewal of marketing authorisation, 1 procedure number (Paragraph 4.2.) - 4000.00 EUR

To receive the prepayment invoice, please send the Payment Application (download here) to e-mail: rekini@zva.gov.lv.

Following the submission of application, an invoice for advance payment shall be sent to the e-mail address you indicated.

Upon making payment, the invoice number and date, as well as name, surname or title of payer must be indicated in the “purpose of payment”.

State Agency of Medicines of Latvia

Jersikas iela 15, Riga, LV-1003, Latvia

VAT reg. No. LV90001836181

The Treasury of the Republic of Latvia

LV24TREL9290579005000

BIC TRELLV 22XXX

Variations to the medicinal products authorisation documentation

After a medicine has been authorised, the terms of the marketing authorisation may subsequently be varied, including:
·   Administrative changes (name of the company and/or address)
·   Quality changes
·   Changes regarding safety, efficacy and pharmacovigilance
Variation notifications are defined as minor Type IA variations, minor Type IB variations or major Type II variations. More information please see in the approved guidelines.

Payment procedure

In order to decrease costs to clients and facilitate administration of payments, the cost of expertise related to variations to marketing authorisation documentation has been included in the annual post-authorisation maintenance fee (Paragraph 5 of the Paid Service Pricelist).

Additional fee for performing tasks for Latvia as a reference member state in a mutual recognition or decentralised procedure (Paragraph 4.4. and 4.5.):

- For type II variation: 1 procedure number (Paragraph 4.4.) - 1000,00 EUR

- For type IB variation: 1 procedure number (Paragraph 4.5.) - 500,00 EUR

For this service advance payment should be made. To receive the prepayment invoice, please send the Payment Application (download here) to e-mail: rekini@zva.gov.lv.